This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
by Zacks Equity Research
Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab
by Zacks Equity Research
Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
by Zacks Equity Research
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.
Marinus (MRNS) Up 20% on Financial and Pipeline Updates
by Zacks Equity Research
Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline candidates targeting major central nervous system disorders.
Elutias (ELUT) Up on Sale of Orthobiologics Business for $35M
by Zacks Equity Research
Elutias (ELUT) gains on divestiture of Orthobiologics business unit for $35 million to Berkeley Biologics LLC, a wholly-owned subsidiary of GNI Group Ltd.
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion for DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) plunges on negative opinion from the Committee for Medicinal Products for Human Use for conditional marketing and full marketing authorization of Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy.
CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer
by Zacks Equity Research
Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.
Vertex (VRTX) Gets Positive CHMP Opinion for Kaftrio Expanded Use
by Zacks Equity Research
Vertex's (VRTX) Kaftrio gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use to treat younger age groups of two to five years old with cystic fibrosis.
Nektar (NKTR) Up on Positive New Data From Eczema Study
by Zacks Equity Research
Nektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated from an early-stage study for treating atopic dermatitis.
Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock Up
by Zacks Equity Research
Lyra (LYRA) gains on positive data from mid-stage study of LYR-220, treating patients with chronic rhinosinusitis who have had ethmoid sinus surgery.
Avalo (AVTX) Up 45% on Deal to Divest Certain Pipeline Drugs
by Zacks Equity Research
Avalo (AVTX) will receive an upfront payment of $150,000 on selling three compounds to AUG Therapeutics. The company is also eligible to receive milestone payments of up to $45 million.
Arcutis (ARQT) Files sNDA for Zoryve in Atopic Dermatitis, Stock Up
by Zacks Equity Research
Arcutis (ARQT) submits sNDA, seeking label expansion of Zoryve (roflumilast) cream 0.15% to treat patients with atopic dermatitis.
Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies
by Zacks Equity Research
The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.
AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo
by Zacks Equity Research
Data from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut the risk of disease progression or death by 38% in certain lung cancer patients.
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
by Zacks Equity Research
Arbutus (ABUS) makes a strategic decision to focus on the development of hepatitis B virus therapies while discontinuing all coronavirus and oral RNA destabilizer programs.
Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio
by Zacks Equity Research
ANI Pharmaceuticals (ANIP), a top-ranked stock, has a diverse portfolio of rare disease and generic medicines. Its Purified Cortrophin Gel is witnessing incremental sales in recent quarters.
Lisata (LSTA) Up on Positive Updates for Pancreatic Cancer Study
by Zacks Equity Research
Lisata's (LSTA) shares gain on a favorable outcome in interim futility analysis of its lead candidate, LSTA1, for pancreatic cancer.
NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake
by Zacks Equity Research
With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a unique $1 per share dividend.
Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up
by Zacks Equity Research
Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies.
BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study
by Zacks Equity Research
Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its CardiAMP cell therapy is unlikely to achieve the primary endpoint for the treatment of heart failure.
Insmed (INSM) Up on Positive Data From MAC Lung Disease Study
by Zacks Equity Research
Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.
AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why
by Zacks Equity Research
AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
by Zacks Equity Research
SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.
FTC Allows Amgen (AMGN) to Proceed With $28B Horizon Buyout
by Zacks Equity Research
Per the settlement terms, Amgen (AMGN) is prohibited from bundling its products with Horizon's Tepezza or Krystexxa. Amgen expects to complete the Horizon acquisition before 2023-end.
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
by Zacks Equity Research
Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients.